Form 8-K - Current report:
SEC Accession No. 0001104659-25-047867
Filing Date
2025-05-13
Accepted
2025-05-13 16:35:42
Documents
15
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2514952d1_8k.htm   iXBRL 8-K 25950
2 EXHIBIT 99.1 tm2514952d1_ex99-1.htm EX-99.1 86867
3 GRAPHIC tm2514952d1_ex99-1img001.jpg GRAPHIC 3986
  Complete submission text file 0001104659-25-047867.txt   306496

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ckpt-20250513.xsd EX-101.SCH 3026
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ckpt-20250513_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ckpt-20250513_pre.xml EX-101.PRE 22366
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2514952d1_8k_htm.xml XML 3689
Mailing Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453
Business Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453 781-652-4500
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

EIN.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38128 | Film No.: 25940772
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)